|
Clinical features
|
Splitting
|
Amplification
|
|---|
| |
Frequency
|
P value
|
Frequency
|
P value
|
|---|
|
Gender
|
|
Male
|
47.2% (50/106)
|
0.089 a
|
86.2% (94/109)
|
1.000 a
|
|
Female
|
28.6% (8/28)
| |
89.3% (25/28)
| |
|
Age
|
|
< 60
|
47.8% (33/69)
|
0.274
|
87.1% (61/70)
|
1.000 a
|
|
≥ 60
|
38.5% (25/65)
| |
86.6% (58/67)
| |
|
Tumor size
|
|
T1, T2
|
50.0% (10/20)
|
0.511
|
85.0% (17/20)
|
0.728 a
|
|
T3, T4
|
42.1% (48/114)
| |
87.2% (102/117)
| |
|
Lymph node metastasis
|
|
N0
|
30.2% (19/63)
|
0.004
|
79.4% (50/63)
|
0.022 a
|
|
N1
|
54.9% (39/71)
| |
93.2% (69/74)
| |
|
Stage
|
|
I, IIa
|
29.3% (17/58)
|
0.004
|
79.3% (46/58)
|
0.039 a
|
|
IIb, III, IV
|
53.9% (41/76)
| |
92.4% (73/79)
| |
|
Differentiation
|
|
G1
|
40.7% (11/27)
|
0.762 b
|
85.2% (23/27)
|
0.118 b
|
|
G2
|
41.7% (30/72)
| |
91.9% (68/74)
| |
|
G3
|
48.6% (17/35)
| |
77.8% (28/36)
| |
-
a Fisher’s test.
-
b Kruskal–Wallis test.
- The P value which is not labeled with “a” or “b” is assessed by χ2 test.
